HISHOH Biopharma is developing a novel synthetic compound, HSO-001, licensed from Daiichi Sankyo. This potent TLR4 agonist is designed for use in combination with existing sublingual allergen immunotherapy (SLIT) to enhance efficacy and significantly reduce the treatment period, aiming for “remission of allergy.” The focus is on SLIT for conditions such as allergic rhinitis, asthma, atopic dermatitis, and food allergies. The company is actively seeking investors to conduct a Phase 1 study in Australia in Q1 2025 to gather safety and biomarker data.
選單